Learn about groundbreaking research in early detection and prevention of multiple myeloma in this medical lecture from Dr. Irene Ghobrial at Dana-Farber Cancer Institute. Explore the latest developments in identifying precursor conditions like smoldering multiple myeloma and monoclonal gammopathy of undetermined significance (MGUS), with detailed insights into screening methods, risk stratification, and innovative treatment approaches. Discover the progress of the PROMISE study, examining patient outcomes, survival rates, and cutting-edge therapeutic options including immunotherapy and CAR-T cell therapy. Gain valuable knowledge about the Center for Prevention of Progression's efforts in early intervention and their comprehensive approach to preventing active myeloma development through various clinical trials and treatment strategies.
Early Detection and Prevention of Multiple Myeloma Progression
Dana-Farber Cancer Institute via YouTube
Overview
Syllabus
Introduction
How do we do that
What causes multiple myeloma
Diagnosis of multiple myeloma
Risk stratification
How to screen
The promise study
How are we doing that
Our numbers so far
Our numbers in general
What did we find
The numbers
Overall survival
Early Monoclonal Gametes
Risk Stratigraphy
Single Cell Sequencing
Immune MRZ
Early Treatment
Immunotherapy
CART therapy
Conclusion
Taught by
Dana-Farber Cancer Institute
Related Courses
-
Management Updates for Smoldering Multiple Myeloma and MGUS - Prevention and Progression
-
Future Directions for Novel and Next Generation Therapy in Multiple Myeloma
-
CAR T-Cell Therapy for Multiple Myeloma Treatment and New Therapeutic Approaches
-
Future of Novel Next-Generation Therapy in the Management of Relapsed/Refractory Multiple Myeloma
-
Bispecific Antibody Therapy for Treating Relapsed and Refractory Multiple Myeloma
-
Bispecific Antibodies in Multiple Myeloma
